These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Comparative efficacy of red cell and plasma haloperidol as predictors of clinical response in schizophrenia. Smith RC; Baumgartner R; Shvartsburd A; Ravichandran GK; Vroulis G; Mauldin M Psychopharmacology (Berl); 1985; 85(4):449-55. PubMed ID: 2862652 [TBL] [Abstract][Full Text] [Related]
43. Further studies on the mechanism of antipsychotic action: potentiation by alpha-methyltyrosine of thioridazine effects in chronic schizophrenics. Carlsson A; Roos BE; Wålinder J; Skott A J Neural Transm; 1973; 34(2):125-32. PubMed ID: 4146641 [No Abstract] [Full Text] [Related]
44. Further studies of the butyrophenone, CI-601, in chronic schizophrenic patients. Edwards JG; Simpson GM Curr Ther Res Clin Exp; 1968 Oct; 10(10):520-8. PubMed ID: 4971467 [No Abstract] [Full Text] [Related]
45. Therapeutic trial of lysergic Acid diethylamide (LSD) and thioridazine in chronic schizophrenia. Shirvaikar RV; Kelkar YW Neurol India; 1966; 14(2):97-101. PubMed ID: 5330728 [No Abstract] [Full Text] [Related]
46. Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. Chemically unrelated antipsychotics as therapeutic alternatives. Serafetinides EA; Collins S; Clark ML J Nerv Ment Dis; 1972 Jan; 154(1):31-42. PubMed ID: 4550211 [No Abstract] [Full Text] [Related]
47. Haloperidol, thioridazine and placebo in mentally subnormal patients-serum levels and clinical effects. Väisänen K; Viukari M; Rimón R; Räisänen P Acta Psychiatr Scand; 1981 Mar; 63(3):262-71. PubMed ID: 7015792 [TBL] [Abstract][Full Text] [Related]
48. The behavioral effects of nicotinamide adenine dinucleotide in chronic schizophrenia. Meltzer H; Shader R; Grinspoon L Psychopharmacologia; 1969; 15(2):144-52. PubMed ID: 4310848 [No Abstract] [Full Text] [Related]
49. Flupenthixol in chronic schizophrenic inpatients: a controlled comparison with haloperidol. Ehmann TS; Delva NJ; Beninger RJ J Clin Psychopharmacol; 1987 Jun; 7(3):173-5. PubMed ID: 3298328 [TBL] [Abstract][Full Text] [Related]
50. A clinical study with propericiazine in chronic psychotic patients. Deutsch M; Ananth JV; Ban TA Curr Ther Res Clin Exp; 1971 Jun; 13(6):353-8. PubMed ID: 4397391 [No Abstract] [Full Text] [Related]
51. Lateral ventricular enlargement and clinical response in schizophrenia. Smith RC; Baumgartner R; Ravichandran GK; Mauldin M; Burd A; Vroulis G; Gordon J; Calderon M Psychiatry Res; 1985 Mar; 14(3):241-53. PubMed ID: 3858896 [TBL] [Abstract][Full Text] [Related]
52. Loxapine succinate: a double-blind comparison with haloperidol and placebo in acute schizophrenics. Selman FB; McClure RF; Helwig H Curr Ther Res Clin Exp; 1976 Jun; 19(6):645-52. PubMed ID: 819222 [No Abstract] [Full Text] [Related]
53. Plasma levels and clinical effects of thioridazine and thiothixene. Bergling R; Mjorndal T; Oreland L; Rapp W; Wold S J Clin Pharmacol; 1975; 15(2-3):178-86. PubMed ID: 1091665 [TBL] [Abstract][Full Text] [Related]